Condition: Schizophrenia · Bipolar Disorder · Alzheimer Disease · Sponsor: Hôpital le Vinatier
The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators demonstrated significantly lower concentrations of neurofilaments in CSF of psychiatric patients compared to neurodegenerative diseases. The main objective of this study is to validate the plasma assay of neurofilament light chain as a biomarker for the differential diagnosis of psychiatric or neurodegenerative cognitive impairment. Other biomarkers of interest (Tau, TDP-43, GFAP and UCH-L1) will also be analyzed. A sub-part of this study will also focus on the retrospective analysis of the CSF/Plasma correlations of the different biomarkers mentioned above from tube bottom samples taken in routine care.
This description comes directly from the study's public registry record.
Dorey Jean-Michel, MD,PHD · 0437915249 · jean-michel.dorey@ch-le-vinatier.fr
SARTELET lydie · 0437915531 · lydie.sartelet@ch-le-vinatier.fr
Always discuss trial participation with your own doctor first.
| HCL Consultation mémoire Neurologique -Hôpital Neurologique | Bron, France | Recruiting |
| Centre Hospitalier Le Vinatier | Bron, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04946916